The Pandora’s Box of novel technologies that may revolutionize lung cancer
- Publisher:
- Elsevier
- Publication Type:
- Journal Article
- Citation:
- Lung Cancer, 2021, 159, pp. 34-41
- Issue Date:
- 2021-07-19
Recently Added
Filename | Description | Size | |||
---|---|---|---|---|---|
1-s2.0-S0169500221004712-main.pdf | Published version | 2.73 MB | Adobe PDF |
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is new to OPUS and is not currently available.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Rad, HS | |
dc.contributor.author | Rad, HS | |
dc.contributor.author | Shiravand, Y | |
dc.contributor.author | Radfar, P | |
dc.contributor.author | Arpon, D | |
dc.contributor.author | Warkiani, ME | |
dc.contributor.author | O'Byrne, K | |
dc.contributor.author | Kulasinghe, A | |
dc.date.accessioned | 2022-03-08T06:16:07Z | |
dc.date.available | 2021-06-27 | |
dc.date.available | 2022-03-08T06:16:07Z | |
dc.date.issued | 2021-07-19 | |
dc.identifier.citation | Lung Cancer, 2021, 159, pp. 34-41 | |
dc.identifier.issn | 0169-5002 | |
dc.identifier.issn | 1872-8332 | |
dc.identifier.uri | http://hdl.handle.net/10453/155073 | |
dc.description.abstract | Non-small cell lung cancer (NSCLC) is one of the most common cancers globally and has a 5-year survival rate ~20%. Immunotherapies have demonstrated long-term and durable responses in NSCLC patients, although they appear to be effective in only a subset of patients. A more comprehensive understanding of the underlying tumour biology may contribute to identifying those patients likely to achieve optimal outcomes. Profiling the tumour microenvironment (TME) has shown to be beneficial in addressing fundamental tumour-immune cell interactions. Advances in multiplexing immunohistochemistry and molecular barcoding has led to recent advances in profiling genes and proteins in NSCLC. Here, we review the recent advancements in spatial profiling technologies for the analysis of NSCLC tissue samples to gain new insights and therapeutic options for NSCLC. The combination of spatial transcriptomics combined with advanced imaging is likely to lead to deep insights into NSCLC tissue biology, which can be a powerful tool to predict likelihood of response to therapy. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.publisher | Elsevier | |
dc.relation.ispartof | Lung Cancer | |
dc.relation.isbasedon | 10.1016/j.lungcan.2021.06.022 | |
dc.rights | This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.subject | 1103 Clinical Sciences, 1112 Oncology and Carcinogenesis | |
dc.subject.classification | Oncology & Carcinogenesis | |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Immunohistochemistry | |
dc.subject.mesh | Immunotherapy | |
dc.subject.mesh | Lung Neoplasms | |
dc.subject.mesh | Tumor Microenvironment | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung | |
dc.subject.mesh | Lung Neoplasms | |
dc.subject.mesh | Immunotherapy | |
dc.subject.mesh | Immunohistochemistry | |
dc.subject.mesh | Tumor Microenvironment | |
dc.title | The Pandora’s Box of novel technologies that may revolutionize lung cancer | |
dc.type | Journal Article | |
utslib.citation.volume | 159 | |
utslib.location.activity | Ireland | |
utslib.for | 1103 Clinical Sciences | |
utslib.for | 1112 Oncology and Carcinogenesis | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Engineering and Information Technology | |
pubs.organisational-group | /University of Technology Sydney/Strength - CHT - Health Technologies | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering | |
pubs.organisational-group | /University of Technology Sydney/Strength - IBMD - Initiative for Biomedical Devices | |
pubs.organisational-group | /University of Technology Sydney/Centre for Health Technologies (CHT) | |
utslib.copyright.status | recently_added | * |
pubs.consider-herdc | false | |
dc.date.updated | 2022-03-08T06:16:06Z | |
pubs.publication-status | Published | |
pubs.volume | 159 |
Abstract:
Non-small cell lung cancer (NSCLC) is one of the most common cancers globally and has a 5-year survival rate ~20%. Immunotherapies have demonstrated long-term and durable responses in NSCLC patients, although they appear to be effective in only a subset of patients. A more comprehensive understanding of the underlying tumour biology may contribute to identifying those patients likely to achieve optimal outcomes. Profiling the tumour microenvironment (TME) has shown to be beneficial in addressing fundamental tumour-immune cell interactions. Advances in multiplexing immunohistochemistry and molecular barcoding has led to recent advances in profiling genes and proteins in NSCLC. Here, we review the recent advancements in spatial profiling technologies for the analysis of NSCLC tissue samples to gain new insights and therapeutic options for NSCLC. The combination of spatial transcriptomics combined with advanced imaging is likely to lead to deep insights into NSCLC tissue biology, which can be a powerful tool to predict likelihood of response to therapy.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph